Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KA2507 是一种具有口服活性的选择性HDAC6抑制剂, 其IC50值为 2.5 nM。它有抗肿瘤活性和免疫调节作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 789 | 现货 | ||
5 mg | ¥ 1,990 | 现货 | ||
10 mg | ¥ 3,230 | 现货 | ||
25 mg | ¥ 5,330 | 现货 | ||
50 mg | ¥ 7,520 | 现货 | ||
100 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 213 | 现货 |
产品描述 | KA2507 is a potent and selective HDAC6 inibitor with an IC50 of 2.5nM. |
靶点活性 | HDAC6:2.5nm |
体外活性 | At concentrations selective for HDAC6 inhibition, KA2507 did not inhibit in vitro proliferation of mouse or human cancer cells. |
体内活性 | KA2507 (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model. KA2507 also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models. Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I. KA2507 exhibits poor oral bioavailability (mice 15%) and Cmax (mice 300 ng/mL) following oral administration (mice 200 mg/kg).[1] |
分子量 | 322.32 |
分子式 | C16H14N6O2 |
CAS No. | 1636894-46-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (186.15 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1025 mL | 15.5125 mL | 31.0251 mL | 77.5627 mL |
5 mM | 0.6205 mL | 3.1025 mL | 6.205 mL | 15.5125 mL | |
10 mM | 0.3103 mL | 1.5513 mL | 3.1025 mL | 7.7563 mL | |
20 mM | 0.1551 mL | 0.7756 mL | 1.5513 mL | 3.8781 mL | |
50 mM | 0.0621 mL | 0.3103 mL | 0.6205 mL | 1.5513 mL | |
100 mM | 0.031 mL | 0.1551 mL | 0.3103 mL | 0.7756 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
KA2507 1636894-46-6 Chromatin/Epigenetic DNA Damage/DNA Repair HDAC KA 2507 modulatory KA-2507 colorectal Histone deacetylases immune cancer antitumor Inhibitor melanoma inhibit inhibitor